Dr. Steven Jay Isakoff, MD, PhD

Dr. Isakoff practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Isakoff's NPI, 1447205042, was assigned on May 23, 2006. Dr. Isakoff graduated from New York University School of Medicine in 2000. Dr. Isakoff holds Massachusetts license 218952.

Dr. Isakoff's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Isakoff's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Isakoff is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Isakoff to 3 more hospitals, 2 medical groups and 1 community health center, each named with a free account. Dr. Isakoff's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Isakoff practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Isakoff's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Isakoff is licensed in Massachusetts.

CMS data shows 492 Medicare services from Dr. Isakoff across 4 procedure codes in 2024, for 217 Medicare patients. Medicare paid $32,719 for them.

CMS counts 217 Medicare patients who saw Dr. Isakoff in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have cancer, and 65% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.44, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Isakoff's median patient age at 71, with 94% women.

In 2024, Dr. Isakoff wrote 254 Medicare Part D claims for 81 patients. 86% of them were for generic drugs. CMS names the drug for 159 of them, across 5 drugs with 11 or more claims each, at $374,366 in total drug cost. In 2023, CMS named 188 claims across 5 drugs.

Dr. Isakoff accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Isakoff as offering telehealth.

Dmand AI links 117 papers to Dr. Isakoff, published from 2010 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Triple Negative Breast Neoplasms. Dr. Isakoff has published most often in Breast Cancer Res Treat. Dr. Isakoff's most frequent co-authors are Aditya Bardia, MD, Laura M. Spring, MD and Leif William Ellisen, MD, PhD.

Dmand AI links Dr. Isakoff to 10 clinical trials, 5 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Breast Neoplasms, Triple Negative Breast Neoplasms and Breast Diseases. Dana-Farber Cancer Institute sponsors the most, 3. Open Payments lists research payments to Dr. Isakoff that name 1 trial.

CMS Open Payments shows 74 general payments to Dr. Isakoff from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Genentech, Inc. paid the most, $13,418. It also lists 14 research payments totaling $8,922 from 2016 to 2024, naming 1 clinical trial.

Dr. Isakoff graduated from New York University School of Medicine in 2000.